BRCA2 and cancer: Given the observed hypersensitivity of a broad range of BRCA2-defective cancer cells to NSC617145, we tested the in vivo response of BRCA2-deficient tumors to the WRNi using xenograft tumor models in athymic nude mice (Fig. 8c).